Starting HRT After 60: The Timing Question
SaveBeginning hormone therapy after 60 is sometimes reasonable but carries a less favorable balance than starting earlier. The timing hypothesis suggests estrogen helps most when begun before 60 or within 10 years of menopause; later starts raise clot, stroke, and heart risks, so non-hormonal and local options are often weighed first.
Last updated: July 2026
What is the timing hypothesis?
The timing hypothesis proposes that when hormone therapy begins matters as much as whether it is used. Estrogen started close to menopause appears to support blood-vessel health, whereas the same hormone started years later, in vessels that have already aged, may do more harm than good 3Ref 3Hodis HN, Mack WJ, Henderson VW, et al. (2016).Vascular effects of early versus late postmenopausal treatment with estradiol.ELITE trial: estradiol slowed early atherosclerosis progression when started within six years of menopause but not ten or more years out.. According to the North American Menopause Society, this is why guidance frames the window before 60, or within 10 years of the final period, as the most favorable time to start 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.. The pattern emerged when researchers re-examined why early trials in older women showed harm while studies of recently menopausal women did not 5Ref 5Manson JE, Chlebowski RT, Stefanick ML, et al. (2013).Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.WHI intervention and extended post-stopping analysis supporting age and time since menopause as drivers of the risk-benefit balance.. Age and time since menopause, not a single birthday, drive the balance.
Why does starting HRT after 60 carry more risk?
Risk rises with later starts mainly because the cardiovascular system changes with age. The 2002 Women's Health Initiative enrolled women at an average age of 63, many more than a decade past menopause, and it was in this older group that combined therapy showed higher rates of heart events, stroke, and clots 2Ref 2Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002).Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.The 2002 WHI trial enrolled women at an average age of 63, many over a decade past menopause, the older group in which combined therapy showed cardiovascular harm.. Starting estrogen in arteries that already carry early plaque may destabilize it rather than protect it 3Ref 3Hodis HN, Mack WJ, Henderson VW, et al. (2016).Vascular effects of early versus late postmenopausal treatment with estradiol.ELITE trial: estradiol slowed early atherosclerosis progression when started within six years of menopause but not ten or more years out.. According to the North American Menopause Society, absolute risks of stroke and venous clots climb with age regardless of hormones, so adding oral estrogen later compounds a rising baseline 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.. Transdermal, lower-dose forms are generally preferred if therapy is started at all 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause..
Can HRT ever start later than 60?
Later initiation is not forbidden; it is a more cautious, individualized decision. For a healthy woman with severe symptoms and low cardiovascular risk, a clinician may still consider low-dose transdermal estrogen after weighing the trade-offs 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.. The ELITE trial found that estradiol slowed early atherosclerosis when started within six years of menopause but not when started ten or more years out, illustrating why timing shifts the calculus 3Ref 3Hodis HN, Mack WJ, Henderson VW, et al. (2016).Vascular effects of early versus late postmenopausal treatment with estradiol.ELITE trial: estradiol slowed early atherosclerosis progression when started within six years of menopause but not ten or more years out.. The KEEPS trial, in women within three years of menopause, found early hormone therapy did not worsen markers of atherosclerosis over about four years 4Ref 4Harman SM, Black DM, Naftolin F, et al. (2014).Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.KEEPS trial in women within three years of menopause: early hormone therapy did not worsen atherosclerosis markers over about four years.. For women who reach menopause early, before 45, the clock is different, and earlier, longer therapy is generally advised 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause..
What options help later starters?
Plenty of effective options exist for women who begin menopause care after 60. Local vaginal estrogen treats vaginal dryness and urinary symptoms with minimal absorption, and is considered appropriate at almost any age 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.. For hot flashes, the 2023 nonhormone position statement of the North American Menopause Society supports cognitive behavioral therapy, certain antidepressants, and newer targeted medicines as evidence-based alternatives 6Ref 6The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.Non-hormonal alternatives — cognitive behavioral therapy, antidepressants, and newer targeted therapies — for symptom relief in women who are not candidates for late-start systemic estrogen.. Estrogen also protects bone, so where systemic therapy is not chosen, other treatments can preserve bone strength and lower fracture risk 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.. According to that guideline, non-hormonal care can meaningfully reduce symptoms without the cardiovascular concerns of late-start systemic estrogen 6Ref 6The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.Non-hormonal alternatives — cognitive behavioral therapy, antidepressants, and newer targeted therapies — for symptom relief in women who are not candidates for late-start systemic estrogen..
When starting HRT after 60 needs a specialist
A clinician can turn the timing question into a personal risk assessment rather than a yes-or-no answer. Someone considering hormone therapy at 62 benefits from a review of heart and stroke risk, bone health, symptom severity, and the benefits and risks of HRT in their specific situation 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.. A gynecologist or menopause-experienced clinician can compare low-dose transdermal therapy against non-hormonal routes and help weigh them 6Ref 6The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.Non-hormonal alternatives — cognitive behavioral therapy, antidepressants, and newer targeted therapies — for symptom relief in women who are not candidates for late-start systemic estrogen.. Because the evidence rewards individualized timing over blanket rules, an informed conversation is especially valuable after 60 5Ref 5Manson JE, Chlebowski RT, Stefanick ML, et al. (2013).Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.WHI intervention and extended post-stopping analysis supporting age and time since menopause as drivers of the risk-benefit balance.. Gale can help you prepare for that conversation.
Common questions
Related
Menopause & midlife
HRT and Heart Disease: The Timing HypothesisMenopause & midlife
HRT Explained: What Hormone Therapy Actually DoesMenopause & midlife
When HRT Isn't Working: Adjusting the Plan
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
Weighing HRT after 60: when to get review
- —A personal history of blood clots, stroke, heart disease, or breast cancer makes late-start systemic hormone therapy higher-risk and is a reason to seek specialist review.
- —Sudden breathlessness, chest pain, or a hot, swollen, painful calf can signal a blood clot and is a reason to seek urgent medical care.
- —Any postmenopausal bleeding is a reason to arrange evaluation before or during hormone therapy.
- —New weakness, facial droop, or trouble speaking can signal a stroke and is a reason to call 911 right away.
This article is general health education, not medical advice. Whether to start hormone therapy after 60 is an individualized decision that belongs with a gynecologist or a menopause-experienced clinician.
References
- 1.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Timing hypothesis; the more favorable window before 60 or within 10 years of menopause; age-related rise in stroke and clot risk; transdermal and low-dose preference; local vaginal estrogen appropriate at most ages; longer therapy for early menopause.
- 2.Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.288.3.321 ✓The 2002 WHI trial enrolled women at an average age of 63, many over a decade past menopause, the older group in which combined therapy showed cardiovascular harm.
- 3.Hodis HN, Mack WJ, Henderson VW, et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. doi:10.1056/NEJMoa1505241 ✓ELITE trial: estradiol slowed early atherosclerosis progression when started within six years of menopause but not ten or more years out.
- 4.Harman SM, Black DM, Naftolin F, et al. (2014). Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of Internal Medicine. doi:10.7326/M14-0353 ✓KEEPS trial in women within three years of menopause: early hormone therapy did not worsen atherosclerosis markers over about four years.
- 5.Manson JE, Chlebowski RT, Stefanick ML, et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. doi:10.1001/jama.2013.278040 ✓WHI intervention and extended post-stopping analysis supporting age and time since menopause as drivers of the risk-benefit balance.
- 6.The North American Menopause Society (Menopause Society) (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002200 ✓Non-hormonal alternatives — cognitive behavioral therapy, antidepressants, and newer targeted therapies — for symptom relief in women who are not candidates for late-start systemic estrogen.
6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy